Core Viewpoint - The approval of Boan Bio's product, Bo Youjing® (Aflibercept intravitreal injection solution), by the National Medical Products Administration of China marks a significant advancement in the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) in adults, with plans for commercialization in collaboration with a leading ophthalmic pharmaceutical platform, EOCON Vision [1] Group 1 - Bo Youjing® is a biosimilar to EYLEA®, with its active ingredient Aflibercept being a humanized fusion protein that targets a broader range of factors compared to anti-VEGF monoclonal antibodies, effectively inhibiting intraocular VEGF and improving vision with long-term efficacy and good overall safety [1][2] - The global indications for EYLEA® include nAMD, DME, retinal vein occlusion (RVO) with macular edema, diabetic retinopathy (DR), myopic choroidal neovascularization (mCNV), and retinopathy of prematurity (ROP), while in China, it is approved for nAMD and DME [1] Group 2 - The development of Bo Youjing® adhered strictly to biosimilar guidelines, demonstrating high similarity to the reference drug in quality, efficacy, safety, and immunogenicity, with Phase I and III clinical trials showing significant improvements in best-corrected visual acuity (BCVA) compared to the reference group [2] - The Phase III clinical trial results indicated that Bo Youjing® achieved clinically significant improvements in BCVA at multiple time points (4, 8, 12, 16, 20, and 24 weeks), meeting all study endpoints with rapid and sustained efficacy [2] Group 3 - To expedite the availability of Bo Youjing® to more patients, the company partnered with EOCON Vision in 2020 to conduct Phase III clinical trials and granted EOCON exclusive promotion and commercialization rights in mainland China [3] - EOCON Vision, as a leading ophthalmic pharmaceutical platform, focuses on integrated capabilities in research, manufacturing, and commercialization, with a portfolio of 43 products and a professional commercial team covering over 20,000 hospitals nationwide [3] - The collaboration aims to enhance the market launch of Bo Youjing®, improve patient accessibility to medication, reduce treatment burdens, and create new growth opportunities for the company [3]

Core Viewpoint - The company has received approval from the National Medical Products Administration of China for its self-developed product, Bo You Jing (Aflibercept intravitreal injection solution), to treat adult neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) [1] Group 1: Product Overview - Bo You Jing is a biosimilar to EYLEA, with the active ingredient Aflibercept, which binds to a broader range of targets compared to anti-VEGF monoclonal antibodies [1] - Aflibercept is an essential first-line treatment for various retinal diseases, effectively improving vision with long-lasting efficacy and good overall safety and tolerability [1] Group 2: Clinical Development - The development of Bo You Jing strictly followed biosimilar guidelines, demonstrating high similarity to the reference drug in quality, efficacy, safety, and immunogenicity [2] - Phase I clinical trial results showed comparable safety and tolerability between Bo You Jing and the reference drug, while Phase III trials indicated significant improvements in best-corrected visual acuity (BCVA) at multiple time points [2] Group 3: Market Potential - The market for anti-angiogenic drugs for eye diseases in China is rapidly growing, with a projected increase from RMB 1.27 billion in 2018 to RMB 4.99 billion by 2024, reflecting a compound annual growth rate of 25.6% [3] - The company has partnered with a leading ophthalmic pharmaceutical platform, Eucan Vision, to conduct Phase III clinical trials and grant exclusive commercialization rights in mainland China [3] Group 4: Patient Demographics - In 2024, approximately 148 million adults aged 20 to 79 in China are expected to have diabetes, with 5.2% of them suffering from DME [2] - Age-related macular degeneration (AMD) is a leading cause of vision loss in the elderly, with a prevalence of 20.2% in individuals over 70 years old in China [2]

Core Viewpoint - The approval of OT-702, a biosimilar to EYLEA®, by the National Medical Products Administration of China marks a significant advancement in the treatment options for age-related macular degeneration and diabetic macular edema in adults [1][2]. Group 1: Product Approval - OT-702 has been approved for the treatment of adult patients with neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) in China [1]. - The product was developed in collaboration with Shandong Boan Biotechnology Co., Ltd., which is listed on the Hong Kong Stock Exchange [1]. Group 2: Mechanism of Action - OT-702 functions as a soluble decoy receptor that binds to VEGF-A, VEGF-B, and P1GF, inhibiting downstream signaling pathways of VEGFR, thereby suppressing neovascularization and reducing vascular permeability [2]. - The biosimilar is positioned to treat various retinal and choroidal pathologies associated with neovascularization [2]. Group 3: Market Potential - EYLEA® has received global approval for multiple indications, including nAMD, DME, retinal vein occlusion (RVO) with macular edema, diabetic retinopathy (DR), myopic choroidal neovascularization (mCNV), and retinopathy of prematurity (ROP) [2]. - OT-702 is eligible to apply for approval for all indications for which EYLEA® has been approved in China, according to the guidelines published by the Center for Drug Evaluation [2].

Core Viewpoint - Oculentis Biopharma-B (01477) has received approval from the National Medical Products Administration of the People's Republic of China for OT-702, a biosimilar to EYLEA, for the treatment of adult neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) [1][2] Group 1 - OT-702 is developed in collaboration with Shandong Boan Biotechnology Co., Ltd., which is listed on the Hong Kong Stock Exchange [1] - The partnership agreement established in October 2020 includes joint efforts to advance OT-702's Phase III clinical trials, granting the company exclusive rights for promotion and commercialization in China [1] Group 2 - OT-702 functions as a soluble decoy receptor that binds to VEGF-A, VEGF-B, and P1GF, blocking downstream signaling pathways of VEGFR, inhibiting neovascularization, and reducing vascular permeability [2] - As a biosimilar to EYLEA, OT-702 can potentially be approved for all indications for which EYLEA has been approved in China, including nAMD and DME [2]

Core Viewpoint - The company, Junshi Biosciences, has announced the completion of the first patient dosing in a Phase 1 clinical trial for its self-developed biosimilar HLX13, targeting unresectable hepatocellular carcinoma (HCC) patients in China [1] Group 1: Clinical Trial Details - The study is an international, multicenter, randomized, double-blind, parallel-controlled Phase 1 clinical trial [1] - The trial aims to evaluate the pharmacokinetic (PK) characteristics, safety, efficacy, and immunogenicity similarities between HLX13 and its reference drug YERVOY® when combined with OPDIVO® in previously untreated advanced HCC patients [1] - Eligible participants will be randomly assigned in a 1:1 ratio to receive either HLX13 or YERVOY® combined with OPDIVO® for the first four cycles, followed by OPDIVO® monotherapy for maintenance treatment every four weeks [1] Group 2: Study Endpoints - The primary endpoint includes the area under the concentration-time curve (AUC0-21d) from pre-dosing to 21 days post-first dosing and the steady-state AUC during the dosing interval after the fourth administration [1] - Secondary endpoints encompass other PK parameters, efficacy assessments, safety, and immunogenicity evaluations [1]

Core Viewpoint - The company, Junshi Biosciences, has announced the completion of the first patient dosing in a Phase 1 clinical trial for its self-developed biosimilar HLX13, targeting unresectable hepatocellular carcinoma (HCC) patients in China [1] Group 1: Clinical Trial Details - The study is an international, multicenter, randomized, double-blind, parallel-controlled Phase 1 clinical trial [1] - The trial aims to evaluate the pharmacokinetic (PK) characteristics, safety, efficacy, and immunogenicity similarities between HLX13 and its reference drug YERVOY® when combined with OPDIVO® in previously untreated advanced HCC patients [1] - Eligible participants will be randomly assigned in a 1:1 ratio to receive either HLX13 or YERVOY® combined with OPDIVO® for the first four cycles, followed by OPDIVO® monotherapy for maintenance treatment every four weeks [1] Group 2: Study Endpoints - The primary endpoint includes the area under the concentration-time curve (AUC0-21d) from pre-dosing to 21 days post-first dosing and the steady-state AUC during the dosing interval after the fourth administration [1] - Secondary endpoints encompass other PK parameters, efficacy assessments, safety, and immunogenicity evaluations [1]

Core Insights - Company announced the completion of the first patient dosing in a Phase 1 clinical trial for HLX13, a biosimilar of ipilimumab, for the treatment of unresectable hepatocellular carcinoma (HCC) in China [1] - The trial is a multicenter, randomized, double-blind, parallel-controlled study aimed at evaluating the pharmacokinetics, safety, efficacy, and immunogenicity of HLX13 compared to the original drug YERVOY® in previously untreated advanced HCC patients [1][2] - HLX13 is also being developed for multiple indications including melanoma, renal cell carcinoma, colorectal cancer, non-small cell lung cancer, malignant pleural mesothelioma, and esophageal squamous cell carcinoma [2] - The global sales of ipilimumab are projected to be approximately $2.873 billion in 2024 [3] Group 1 - HLX13 is a biosimilar of ipilimumab, designed to enhance immune response by blocking CTLA-4, thereby targeting tumors [2] - The Phase 1 trial involves a 1:1 random allocation of participants to receive either HLX13 or YERVOY® combined with OPDIVO® treatment [1] - The primary endpoint of the trial is the area under the concentration-time curve (AUC) from dosing to 21 days post-administration [1] Group 2 - The clinical trial application for HLX13 in HCC was approved by the National Medical Products Administration in June 2023 [2] - The company has entered into a licensing agreement with Sandoz AG for the commercialization of HLX13 in the U.S. and select European regions, Japan, Australia, and Canada [2] - The sales figure for ipilimumab indicates a significant market potential for HLX13 as a biosimilar in the oncology sector [3]

Core Viewpoint - 百奥泰 reported a revenue of 684 million yuan for the first three quarters of 2025, representing a year-on-year growth of 17.57%, while the net loss narrowed to 224 million yuan, indicating improved financial performance [1] Group 1: Financial Performance - The company achieved a revenue of 684 million yuan in the first three quarters, marking a 17.57% increase year-on-year [1] - The net loss for the same period was 224 million yuan, showing a reduction in losses compared to the previous year [1] Group 2: Product Development and Approvals - Several products have been approved for sale, including Adalimumab and Tocilizumab in China and other regions, and Bevacizumab in multiple countries [1] - BAT1806 (Tocilizumab) and BAT2206 (Ustekinumab) have been approved in Europe, with sales managed by partners [2][3] - The company is advancing its innovative drug pipeline, with BAT5906 and BAT4406F expected to submit applications for market approval soon [2][3] Group 3: Market Expansion and Strategy - The company is preparing for participation in centralized procurement, optimizing production capacity and supply chain to enhance competitiveness [2] - New guidelines in the EU and the US for biosimilars are expected to lower R&D costs, providing a competitive advantage for the company [2] Group 4: Clinical Trials and Research - BAT6026 is currently in Phase II clinical trials for atopic dermatitis, while BAT8008 is set to begin Phase III trials for cervical cancer and HER2-negative breast cancer in mid-2026 [3] - Ongoing clinical research for BAT8008 in combination with BAT1308 has shown positive efficacy signals, leading to an expansion of the sample size [3] - BAT7111 is in Phase I dose escalation studies, progressing smoothly with three doses explored [3]

Core Insights - Shanghai Junshi Biosciences Co., Ltd. (复宏汉霖) announced that its HLX11 (biosimilar of pertuzumab, marketed as POHERDY in the U.S.) has received FDA approval for interchangeability with the original product PERJETA, making it the first and only biosimilar of PERJETA in the U.S. [1] - HLX11 is the first biosimilar of pertuzumab approved in the U.S. and the first interchangeable biosimilar for cancer treatment approved by the FDA [1] - The company has seven products approved for overseas markets, with four of them approved in the U.S. [1] Product and Market Details - HLX11 targets HER2 receptors and is indicated for metastatic breast cancer, early breast cancer, and adjuvant treatment for high-risk HER2-positive early breast cancer patients [1] - Organon, a New York Stock Exchange-listed company, will handle the commercialization of HLX11 outside of China, following a licensing and supply agreement signed in 2022 [1] Strategic Commitment - The CEO of Junshi Biosciences emphasized the achievement reflects the company's commitment to a sustainable global R&D system and a patient-centered approach, reinforcing its long-term commitment to global expansion [2] - The company aims to accelerate the delivery of quality biopharmaceuticals to benefit more patients worldwide and create greater value for human health [2]

Overview - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that its subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., Ltd., received FDA approval for its self-developed biosimilar POHERDY? (HLX11) for specific indications in HER2-positive metastatic breast cancer [2][6]. Product Information - HLX11 is a biosimilar of Pertuzumab, with a specification of 420mg/14mL (30mg/mL) for intravenous injection [2]. - The approved indications include treatment in combination with Trastuzumab and Docetaxel for adult patients with HER2-positive metastatic breast cancer who have not previously received anti-HER2 treatment or chemotherapy [2]. - It is also indicated for use in early breast cancer as part of a comprehensive treatment plan for HER2-positive locally advanced, inflammatory, or early breast cancer patients [2]. Regulatory Progress - HLX11's registration progress includes: - Acceptance of the marketing authorization application by the National Medical Products Administration of China in December 2024 [3]. - Acceptance of the marketing authorization application by the European Medicines Agency in March 2025 [3]. - Acceptance of the new drug submission by Health Canada in May 2025 [3]. Financial Investment - As of October 2025, the cumulative R&D investment for HLX11 is approximately RMB 225 million (unaudited) [4]. Market Potential - According to IQVIA MIDAS data, the global sales of Pertuzumab products are projected to be approximately $3.304 billion in 2024 [5]. Strategic Impact - The approval of POHERDY? marks the fourth product approved for Fuhong Hanlin in the U.S., enhancing the company's international market presence [6]. - Commercial rights for HLX11 outside of mainland China and Hong Kong, Macau, and Taiwan were granted to Organon LLC in June 2022, allowing Fuhong Hanlin to benefit from sales milestones and royalties following the U.S. approval [6].